Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Conditions
Solid Tumor · Advanced Cancer · Metastatic Cancer · Gastric Cancer · Gastroesophageal Junction Carcinoma · Esophageal Adenocarcinoma · PDAC - Pancreatic Ductal Adenocarcinoma · Biliary Tract Cancer (BTC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Stern Center for Cancer Clinical Trials and Research, Orange, California, United States
UCHealth Cancer Care - Anschutz Medical Campus, Aurora, Colorado, United States
Horizon Oncology Research, LLC., Layfayette, Indiana, United States
Mass General Hospital, Boston, Massachusetts, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
NYU Langone, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Carolina BioOncology Institute, Huntersville, North Carolina, United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Mary Crowley Cancer Research, Dallas, Texas, United States
UW Carbone Cancer Center, Madison, Wisconsin, United States
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
Beijing Cancer Hospital, Beijing, Beijing Municipality, China
Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
HARBIN Medical University Cancer Hospital, Harbin, Heilongjiang, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Hubei Cancer Hospital, Wuhan, Hubei, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality, China
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China